

**Results.** Of 240 hospitals, 39 (16%; 18 large and 21 small/medium-sized) responded. Preauthorization of using broad-spectrum antibiotics and antifungals was found in 4 (10%) and 1 (3%) hospital(s), respectively. Notification of broad-spectrum antibiotics and antifungals was found in 37 (95%) and 2 (5%) hospitals, respectively. The numbers of hospitals that intervened in the use of broad-spectrum antibiotics within 7 and 28 days were 17 (44%) and 34 (87%), respectively; those of antifungals were 3 (8%) and 10 (26%), respectively (Table 1). Interventions to use broad-spectrum antibiotics within 7 days were statistically more frequent in small-/medium-sized hospitals than in large hospitals [13 (61.9%) vs. 4 (22.2%), odds ratio = 5.7, 95% confidence interval = 1.4–23.3,  $p = 0.023$ ]. All hospitals had less-frequent interventions to use antifungals within 7 days than those for antibiotics [3 (14.3%) vs. 0 (0%)] (Table 2).

**Conclusion.** Small-/middle-sized hospitals had more frequent interventions within 7 days of broad-spectrum antibiotics than those of large hospitals, possibly because small-/medium-sized hospitals are agile and have few barriers against interventions to use broad-spectrum antibiotics. Compared with broad-spectrum antibiotics, interventions of antifungals were less frequently conducted in all hospitals. We need to emphasize the importance of AFS in Japan. Further studies on related factors are needed.

**Table 1. Intervention for AMS and AFS**

	Broad-spectrum antibiotics <sup>a</sup> n=39		Antifungals n=39	
	Preauthorization	4	(10.3%)	1
Notification	37	(94.9%)	2	(5.1%)
Intervention within 7 days	17	(43.6%)	3	(7.7%)
Intervention within 28 days	34	(87.2%)	10	(25.6%)

Unless otherwise stated, data are presented as n (%)

AMS, Antimicrobial stewardship; AFS, Antifungal stewardship

<sup>a</sup>3rd-generation and 4th-generation cephalosporins and piperacillin-tazobactam, carbapenem, intravenous quinolone

**Table 2. Comparison between large and small/middle-sized hospitals regarding intervention within 7 days**

	Small/middle-sized hospitals (≥ 501 beds) n=21	Large-sized hospital (≤ 500 beds) n=18	OR	95% CIs	p value
Broad-spectrum antibiotics <sup>a</sup>	13 (61.9%)	4 (22.2%)	5.7	1.4–23.3	0.023
Antifungals	3 (14.3%)	0 (0%)	-	-	-

Unless otherwise stated, data are presented as n (%)

ASP, Antimicrobial stewardship program; AFP, Antifungal stewardship program; OR, Odds ratio; CI, Confidence interval

<sup>a</sup>3rd-generation and 4th-generation cephalosporins and piperacillin-tazobactam, carbapenem, intravenous quinolone

**Disclosures.** All authors: No reported disclosures.

### 2033. A Systematic Review of Systematic Reviews: Procalcitonin in the ICU to Guide Antibiotic Therapy

Joshua York, MBBS<sup>1</sup>; Maithili Varadarajan, MBBS, MSc<sup>2</sup>; James Wilson, MBBS<sup>2</sup>; Gavin Barlow, MBChB, FRCP, DTMH<sup>3</sup>; <sup>1</sup>Hull University Teaching Hospitals NHS Trust, Hull, UK; <sup>2</sup>Hull University Teaching Hospitals, Orpington, UK; <sup>3</sup>Hull University Teaching Hospitals, Hull York Medical School, Hull, UK

**Session:** 236. Antibiotic Stewardship: Global

**Saturday, October 5, 2019: 12:15 PM**

**Background.** Antimicrobial resistance is an emerging global health crisis with overall antimicrobial use a key contributor. Strategies to safely reduce antibiotic course length are important. Procalcitonin (PCT) is a serum biomarker produced in the presence of bacterial infection. There have been many systematic reviews (SRs) evaluating PCT in various populations but its use remains controversial. The aim of this SR of SRs was to evaluate the extent to which PCT in critical care (ICU) impacts antibiotic duration and other reported outcomes.


**Methods.** A systematic search of major databases using an “a priori” strategy and protocol was performed. SRs were included if one of the reported outcomes related to antibiotic duration or initiation in the ICU. Data were extracted by an author, checked and corrected independently by another author. The quality of SRs was assessed by 2 authors independently using AMSTAR II. Disagreements were resolved by consensus with a third author. Results are presented narratively and in tabular format (Table 1).

**Results.** Figure 1 shows the PRISMA diagram. 19 SRs were included. The number of patients included ranged from 308 to 6,037 (median = 1,316) across SRs. Overall, there was a consistent finding of a statistically significant (sf) reduction in antibiotic duration in study groups using PCT cessation protocols (all studies in Table 1). 3 SRs did not contain suitable statistics for inclusion in Table 1. SRs that presented the antibiotic duration outcome as a mean or median difference in exposure days ( $N = 16$ ) showed a median reduction of 2.10 days (range -1.19 to -5) with PCT use. 1 SR found an sf decrease in mortality with PCT use. 4 SRs included antibiotic initiation as an outcome: 2 found an sf decrease in antibiotic prescription rate with PCT; 2 found no difference.

**Conclusion.** SRs have found that PCT use in ICU leads to an sf reduction in antibiotic duration without impacting mortality. There are no data presented in the SRs about the impact of this on antimicrobial resistance. Few SRs detail the infections included; thus the applicability of these findings to a single ICU remains challenging. Other outcomes, such as length of stay, are not affected by PCT use in ICU.



**PRISMA 2009 Flow Diagram**



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).

**Table 1: Summary of mean / median difference in antibiotic duration with the use of PCT**

Population	First Author	Year	Overall number of studies	Overall number of participants	Mean/ median difference (Days)
Mixed ICU	Lam SW	2018	15	6037	-2
Mixed ICU	Agarwal B	2011	6	1976	-5
Mixed ICU	EluMMA	2015	6	979	-1.71
Sepsis (all in ICU)	Iskhova I	2017	10	3489	-1.09
Mixed ICU subset	Shahra B	2017	8	2664	-2.56
Mixed ICU	Huang HB	2017	13	5136	-1.76
Sepsis (all in ICU)	Wirz Y	2018	11	4482	-1.19
HAP and VAP in ICU	Pugh R	2011	3	308	-3.7
Mixed ICU	Westwood M	2015	8	1972	-3.19
Mixed ICU	Zhang T	2017	15	5486	-2.25
Mixed ICU subset	Soni NJ	2013	5	938	-2.05
Mixed ICU	Mullerum DK	2012	7	2131	-1.14
Mixed ICU	Hayland DK	2011	5	626	-2.14
Mixed ICU	Kopertides P	2010	6	3156	-3.17
Sepsis (all but 1 study in ICU)	Andriole ENG	2017	10	1910	-1.28
Respiratory tract infections in ICU	Schwartz P	2017	16	938	-1.23

**Disclosures.** All authors: No reported disclosures.

### 2034. Standardized Point Prevalence Survey on Antibiotic Use to Inform Antimicrobial Stewardship Strategies in the Caribbean

Jenny Hsieh, MSc<sup>1</sup>; Hatim Sati, MD, MPH<sup>1</sup>; Pilar Ramon-Pardo, MD, PhD<sup>1</sup>; Nienke Bruinsma, PhD<sup>1</sup>; Marcelo F. Galas, BSc<sup>1</sup>; Jean Marie Rwangabwoba, MD<sup>2</sup>; Zoila Irene. Fletcher Payton, 2nd Degree in Epidemiologist<sup>3</sup>; Mariano Bonet, MD<sup>3</sup>; Corey A. Forde, MD<sup>4</sup>; Bibi A. Alladin-Karan, MD<sup>5</sup>; Pheona Mohamed-Rambaran, MD<sup>5</sup>; Gemma Chery, MPH<sup>6</sup>; Nalini Singh, MD, MPH<sup>7</sup>; <sup>1</sup>PAHO/WHO, Vienna, Virginia; <sup>2</sup>PAHO/WHO Country Office Barbados, Bridgetown, Saint Michael, Barbados; <sup>3</sup>PAHO/WHO Country Office Guyana, Georgetown, Demerara-Mahaica, Guyana; <sup>4</sup>Queen Elizabeth Hospital, Bridgetown, Saint Michael, Barbados; <sup>5</sup>Georgetown Public Hospital Corporation, Georgetown, Demerara-Mahaica, Guyana; <sup>6</sup>Ministry of Health Saint Lucia, Castries, Castries, Saint Lucia; <sup>7</sup>The George Washington University, Washington, DC

**Session:** 236. Antibiotic Stewardship: Global

**Saturday, October 5, 2019: 12:15 PM**

**Background.** Inappropriate use of antimicrobials is one of the core contributors to antimicrobial resistance. While hospitals create high selection pressures on bacteria due to the high quantity and broader spectrum of antibiotics used, information on antimicrobial use at the patient level in the Caribbean is sparse. In response, PAHO implemented a standardized WHO methodology to engage national leaderships, build local capacity, and facilitate the use of data to inform antimicrobial stewardship programs (ASP) in the Caribbean.

**Methods.** Point prevalence surveys (PPS) were performed in four acute care hospitals in Barbados, Guyana and Saint Lucia between June and July 2018. Medical records of all inpatients were reviewed to collect information on antibiotic use, indications and use of laboratory services (Figure 1). A hospital questionnaire was used to assess hospital infrastructure, policy and practices, and monitoring and feedback systems (Figure 2). Training on PPS methods and electronic data collection tool in REDCap<sup>™</sup> were provided to build local capacity and identify potential ASP leaderships. A standardized data validation, analysis and reporting system was built in R to streamline the process. Results and recommendations were disseminated to national authorities and stakeholders to support hospital and national decision-making and training for healthcare providers (Figure 3).

